MBX

MBX Biosciences, Inc. (MBX) | Rumor.io

MBX Biosciences

MBX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,219

Bullish sentiment (50-day avg)100%

Price to earnings ratio3.74

Market capitalization2.8B

Earnings per share-2.37

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-87M

Social

What share of all stock conversation is about MBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 26

MBX Biosciences stock has reached an all-time high at $66.66 USD.
No further market-relevant information is available in the provided post.
No bearish or negative comments are present in the provided post.

Generated by AI

Sentiment

Of the messages about MBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.43% +4.96
Bearish	—	—	0% 0	7.57% -4.96

Bullish· Sep 22

MBX Biosciences has a strong financial position with a market cap of ~$335.9M, significant cash reserves, and minimal debt.
The company's pipeline for obesity and endocrine treatments may be undervalued, with a potential for a significant price increase.
Positive Phase 2 data for MBX's once-weekly canvuparatide treatment in chronic hypoparathyroidism has put the company on track for Phase 3 in 2026, with analysts predicting a price target of ~$37.71.

Bearish· Sep 22

$MBX's recent momentum has slowed significantly, making a hard drop imminent.
The company has a history of significant losses, with a quarterly loss of $20 million, and is expected to raise capital through a secondary offering.
The market for $MBX's drug is insignificant due to the presence of many effective drugs already in the market and in late-stage trials, making its approval and revenue prospects uncertain.

Generated by AI

Topics

Of the messages about MBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	84.35%
Analysts	—	—	0%	9.41%
Technical Analysis	—	—	50%	4.2%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.13%
Macro	—	—	0%	1.91%

Sep 25

MBX Biosciences priced an upsized public offering of 11,108,055 shares at $18.00 per share, raising $199.9 million.
The company's stock is trading lower after the announcement, with the offering consisting of common stock.
MBX Biosciences is developing precision peptide therapies for endocrine and metabolic disorders through the offering of its common stock.

Generated by AI

Community

Of the messages about MBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	71.43%	42.72%
Newcomers	—	0%	28.57%	57.28%

Jan 29

$MBX is being compared to $MLN, with the author seeming to be expecting a significant move.
The author is speculating about a potential event or news that could impact $MBX.
There is a sense of anticipation among the newcomer, with the author referencing a possible start or continuation of a trend for $MBX.

Generated by AI

News

UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data

1d agoInvesting.com

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX)

6d agoSeeking Alpha

MBX Biosciences at Morgan Stanley conference: pipeline nears key tests

13d agoInvesting.com

MBX Biosciences to Participate in Upcoming Investor Conferences

CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor confer

21d agoYahoo Finance

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

CARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Jeff Held, J.D., as Chief Legal Officer. Mr. Held brings more than three decades of legal, compliance and executive leadership experience across biotechnology, l

22d agoYahoo Finance

MBX Biosciences doses first patient in phase 3 HP trial

1mo agoInvesting.com

Also Discussed

Investors talking about MBX also mention

#	Name	Attention
1	Fortrea Holdings Inc.FTRE	0%0
2	Dianthus Therapeutics Inc.DNTH	0%0
3	TuHURA Biosciences, Inc.HURA	0%0
4	Vestis CorporationVSTS	0%new
5	Credit Suisse Asset Management Income Fund, Inc.CIK	0%new
6	Integra LifeSciences Holdings CorporationIART	0%0
7	KlaytnKLAY	0%0
8	Allied Gaming & Entertainment Inc.AGAE	0%0
9	Fibrobiologics Inc.FBLG	0%0
10	LBAI - Lakeland Bancorp, Inc.	——

MBX Biosciences, Inc.

Healthcare
Biotechnology

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. MBX Biosciences is advancing investigational programs built around its proprietary peptide platform to address conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Its pipeline includes canvuparatide, a parathyroid hormone replacement candidate, as well as additional peptide-based assets in clinical and preclinical development. The company’s work centers on designing long-acting therapies intended to improve treatment convenience and expand options in specialty endocrine care. Based in Carmel, Indiana, MBX Biosciences operates in the biotechnology and specialty therapeutics market, where it contributes to the development of targeted medicines for diseases with significant unmet medical needs.

Website

Location

11711 North Meridian Street

Carmel, IN, 46032

United States

Social

What share of all stock conversation is about MBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 26

MBX Biosciences stock has reached an all-time high at $66.66 USD.
No further market-relevant information is available in the provided post.
No bearish or negative comments are present in the provided post.

Generated by AI

Sentiment

Of the messages about MBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	92.43% +4.96
Bearish	—	—	0% 0	7.57% -4.96

Bullish· Sep 22

MBX Biosciences has a strong financial position with a market cap of ~$335.9M, significant cash reserves, and minimal debt.
The company's pipeline for obesity and endocrine treatments may be undervalued, with a potential for a significant price increase.
Positive Phase 2 data for MBX's once-weekly canvuparatide treatment in chronic hypoparathyroidism has put the company on track for Phase 3 in 2026, with analysts predicting a price target of ~$37.71.

Bearish· Sep 22

$MBX's recent momentum has slowed significantly, making a hard drop imminent.
The company has a history of significant losses, with a quarterly loss of $20 million, and is expected to raise capital through a secondary offering.
The market for $MBX's drug is insignificant due to the presence of many effective drugs already in the market and in late-stage trials, making its approval and revenue prospects uncertain.

Generated by AI

Topics

Of the messages about MBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	84.35%
Analysts	—	—	0%	9.41%
Technical Analysis	—	—	50%	4.2%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.13%
Macro	—	—	0%	1.91%

Sep 25

MBX Biosciences priced an upsized public offering of 11,108,055 shares at $18.00 per share, raising $199.9 million.
The company's stock is trading lower after the announcement, with the offering consisting of common stock.
MBX Biosciences is developing precision peptide therapies for endocrine and metabolic disorders through the offering of its common stock.

Generated by AI

Community

Of the messages about MBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	71.43%	42.72%
Newcomers	—	0%	28.57%	57.28%

Jan 29

$MBX is being compared to $MLN, with the author seeming to be expecting a significant move.
The author is speculating about a potential event or news that could impact $MBX.
There is a sense of anticipation among the newcomer, with the author referencing a possible start or continuation of a trend for $MBX.

Generated by AI

MBX Biosciences

Social

Jul 26

Bullish· Sep 22

Bearish· Sep 22

Sep 25

Jan 29

UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX)

MBX Biosciences at Morgan Stanley conference: pipeline nears key tests

MBX Biosciences to Participate in Upcoming Investor Conferences

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

MBX Biosciences doses first patient in phase 3 HP trial

Also Discussed

MBX Biosciences, Inc.

Company Information

Location

Social

Jul 26

Bullish· Sep 22

Bearish· Sep 22

Sep 25

Jan 29

UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data

MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX)

MBX Biosciences at Morgan Stanley conference: pipeline nears key tests

MBX Biosciences to Participate in Upcoming Investor Conferences

MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

MBX Biosciences doses first patient in phase 3 HP trial

Also Discussed